Global /United States /Healthcare /Drug Manufacturers - General /ALLR

Allarity Therapeutics, Inc.

ALLR

• NASDAQ: ALLR • Delayed

1.38USD 0.7%

As of 15 June 2026, Allarity Therapeutics, Inc. has a market cap of $21.83M USD, ranking #36504 globally and #4953 in the United States. It ranks #3278 in the Healthcare sector, and #1097 in the Drug Manufacturers - General industry.

Global Rank

36504

Country Rank

4953

Sector Rank

3278

Industry Rank

1097

Key Stats

Market Cap

$21.83MUSD

Enterprise Value

$7.99MUSD

Revenue (TTM)

$320.0KUSD

EBITDA (TTM)

-$12.6MUSD

Net Income (TTM)

-$11.23MUSD

PS Ratio

66.7

PB Ratio

2.7

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Thomas Jensen open_in_new

Employees

Founded

2004

Website

allarity.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0.7%	-1.4%	27%	25%	-6.8%	26%	27%	-100%	-100%

News

ALLR Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	ALLR Allarity Therapeutics Inc ISIN: US0167445008 Shares Out.: Shares Outstanding: 15.911M¹ Shares Float: 15.029M² TV: TradingView: NASDAQ: ALLR SA: Stock Analysis: NASDAQ: ALLR YF: Yahoo Finance: ALLR GF: Google Finance: NASDAQ: ALLR NQ: NASDAQ: ALLR BA: Barron's: ALLR MS: Morningstar: XNAS: ALLR	1.38 USD	TV: TradingView: NASDAQ: ALLR SA: Stock Analysis: NASDAQ: ALLR YF: Yahoo Finance: ALLR GF: Google Finance: NASDAQ: ALLR NQ: NASDAQ: ALLR BA: Barron's: ALLR MS: Morningstar: XNAS: ALLR

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Allarity Therapeutics, Inc.

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and recurrent ovarian cancer. The company also develops stenoparib- DRP, a companion diagnostic product used in select patients for stenoparib treatment. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Similar Companies

Industry: Drug Manufacturers - General (United States)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 3M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 3M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 2M%	97.4	United States
Merck & Co., Inc. NYSE: MRK	$274.03B 1M%	15.1	United States
Pfizer Inc. NYSE: PFE	$149.38B 684K%	19.5	United States
Bristol-Myers Squibb Co. NYSE: BMY	$117.58B 539K%	16.8	United States

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 1M%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 1M%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 1M%	20.5	Switzerland
Novo Nordisk A/S CPH: NOVO-B	$181.82B 1.18T DKK 833K%	11.5	Denmark
Sanofi EPA: SAN	$110.1B 95.26B EUR 504K%	19.9	France
GSK plc LSE: GSK	$108.46B 80.96B GBP 497K%	14.6	United Kingdom

chevron_leftBack